Targeting a complement serine protease in vascular disease

In spite of major advances in our knowledge and better treatments, heart attacks, strokes and blood clots in the legs and lungs, continue to major causes of disability and death. Recent studies reveal that a protein (a so-called "serine protease") in our blood, when increased, may heighten the risk of excess blood clot formation in our blood vessels. Our studies are designed to determine how this protein works, and if by blocking its activity, we can prevent excess blood clotting. Our research program may uncover a more effective way to prevent blood vessel disease.

The role of complement factor D (adipsin) in the pathogenesis of the Stargardt phenotype in Abca4-deficient mice

Stargardt disease affects approximately 1:10,000 individuals and causes progressive, irreversible blindness. While primarily a juvenile disease, age of onset can range from childhood to adulthood. Although supportive care can help slow progression, there are currently no approved therapies and all patients are expected to reach legal blindness. Therefore, Stargardt disease represents an urgent unmet medical need.Oak Bay Biosciences, based in Victoria BC, is a preclinical biotechnology company with a goal to develop the first approved therapy for Stargardt disease.